Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq. Upstream had previously expected to ...

Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment ...

Summary. Upstream Bio, Inc. plans to raise $100 million through an IPO to advance its promising Phase 2 drug candidate, verekitug, for severe asthma and chronic rhinosinusitis.

Upstream is also the latest company with a drug in advanced clinical testing to experience IPO success. A majority of the 22 IPOs in 2024 — and nine of the largest 10 offerings — have involved ...

Orbimed is Upstream’s largest shareholder with a 9.9% post-IPO stake, the filing shows. As of the end of June, the company reported its cash position was $235.8 million.

Upstream stock rises 26.5% above IPO price Drug developer valued at $1.1 bln at open Healthcare sector leads US IPO market in 2024 Oct 11 (Reuters) - Shares of Upstream Bio (UPB.O), opens new tab ...

Upstream Bio (NASDAQ:UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public offering. Shares of Upstream (UPB) opened at $21.50, later reaching a high ...

While Upstream had already disclosed its intention to hitch itself to this fall’s lengthening biotech IPO wagon, CAMP4 only announced Monday morning that its goal is also to go public.

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised $255 million at a valuation of about $830 million.

Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug.

Upstream plans to list on the Nasdaq under the symbol UPB. It emerged onto the scene in 2022 with a $200 million Series A round and followed that with a $200 million Series B the following year. Image ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Upstream Bio announced Thursday it priced its ...